Markets:

Overview

News

Currencies

International

Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

22.85 -0.29 (-1.25%)

Streaming Delayed Price Updated: 9:39 AM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024

May 04, 2024

From UroGen Pharma Ltd.

Via Business Wire

New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial

May 04, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024

May 03, 2024

From UroGen Pharma Ltd.

Via Business Wire

Earnings Outlook For UroGen Pharma ↗

March 13, 2024

Via Benzinga

Recap: UroGen Pharma Q3 Earnings ↗

November 14, 2023

Via Benzinga

Preview: UroGen Pharma's Earnings ↗

November 13, 2023

Via Benzinga

UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers

April 17, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

April 15, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals

April 03, 2024

From UroGen Pharma Ltd.

Via Business Wire

The Latest Analyst Ratings for UroGen Pharma ↗

October 04, 2023

Via Benzinga

Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 25, 2024

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

Via Benzinga

URGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023 ↗

March 14, 2024

URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102

March 14, 2024

From UroGen Pharma Ltd.

Via Business Wire

Earnings Scheduled For March 14, 2024 ↗

March 14, 2024

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

Via Benzinga

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 08, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024

March 04, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference

February 26, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Participate at Upcoming Investor Conferences

February 01, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102

January 24, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers

January 17, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Participate in the B. Riley Healthcare Conference

January 11, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 08, 2023

From UroGen Pharma Ltd.

Via Business Wire

Two Months After Hamas Attacks, Gaza Conflict Intensifies As Ceasefire Efforts Falter ↗

December 07, 2023

Two months after Hamas attacks, US President Biden, UNSC & King of Jordan call for ceasefire. Israeli stocks rise, US envoy to UN against ceasefire. Investigations into civilian casualties & use of...

Via Benzinga

UroGen Pharma Reports Third Quarter 2023 Financial Results

November 14, 2023

From UroGen Pharma Ltd.

Via Business Wire

UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology

November 13, 2023

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023

November 07, 2023

From UroGen Pharma Ltd.

Via Business Wire

Cathie Wood's ARK Israel Innovative Tech ETF Braces For Impact Amid Regional Warfare: 10 Stocks To Watch ↗

October 09, 2023

Discover how Cathie Wood's ARK Israel Innovative Tech ETF responds to the Israel-Hamas conflict. Explore its portfolio performance and top Israeli stocks to watch amidst geopolitical turmoil.

Via Benzinga

Topics ETFs

Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024

October 03, 2023

From UroGen Pharma Ltd.

Via Business Wire

Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors

September 11, 2023

From Eledon Pharmaceuticals, Inc.

Via GlobeNewswire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 08, 2023

From UroGen Pharma Ltd.

Via Business Wire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.